Prescriptions for GLP-1 receptor agonists have surged more than fourfold since 2021. At the same time, population-level obesity rates have begun to edge lower. The alignment is no coincidence. New real-world data from electronic health records and national surveys suggest these medications, once viewed primarily as diabetes treatments, are exerting measurable effects on one of the country’s most stubborn public health challenges.
EPIC Research examined records from the COSMOS dataset, which draws from Epic Systems software used across thousands of U.S. hospitals and clinics and covers more than 300 million patients. Between the second quarter of 2021 and the first quarter of 2026, GLP-1 prescriptions per 100,000 U.S. adults climbed from 1,884 to 8,819. Over that same span the share of patients classified as obese fell from 42% to 41%. Among those who actually received a GLP-1 prescription the decline proved sharper, from 75% to 69%. (Gizmodo)
Short. Punchy. Telling.
Other indicators reinforce the pattern. Gallup polling showed self-reported adult obesity dropping nearly three percentage points to 37% in 2025 after hovering near 40% in prior years. Use of weight-loss injections more than doubled in under two years, reaching 12.4% of respondents by mid-2025 from 5.8% in early 2024. Self-reporting carries limits. People tend to underestimate weight. Yet the trend lines match broader CDC observations of declining obesity prevalence between 2023 and 2024. (Vox, published Nov. 1, 2025)
Clinical evidence has long predicted such outcomes. In the STEP 1 trial published in the New England Journal of Medicine, adults with overweight or obesity who took 2.4 mg of semaglutide weekly lost an average 14.9% of body weight over 68 weeks compared with 2.4% on placebo. More than half achieved at least 15% loss. Cardiometabolic markers improved in tandem. The SELECT trial, involving 17,604 participants with established cardiovascular disease but no diabetes, delivered a 20% reduction in major adverse cardiac events alongside sustained weight loss averaging 10.2% at four years. (NEJM; Nature Medicine)
But. These benefits hinge on continued use.
A large analysis published in The BMJ reviewed 37 studies encompassing 9,341 patients treated with 18 different weight-loss medications, roughly half of them GLP-1 agents including semaglutide and tirzepatide. After discontinuation participants regained weight at an average rate of nearly one pound per month and were projected to return to baseline within 1.7 years. For those on the newer GLP-1 drugs the monthly regain accelerated to 1.8 pounds yet the timeline to pre-treatment weight remained similar at about 1.5 years because initial losses had been greater. Heart health improvements faded on a comparable schedule. “Understanding who does well and who does not is a bit of a ‘holy grail’ question in weight-loss research,” said senior researcher Dimitrios Koutoukidis of Oxford University, “but nobody has the answer to that yet.” (Reuters, Jan. 8, 2026)
Real-world persistence tells a mixed story. FAIR Health data documented a 587% increase in GLP-1 prescriptions for overweight or obesity from 2019 to 2024. CDC figures for 2024 showed 26.5% of adults with diagnosed diabetes using these injectables, with higher uptake among those with greater BMI. Yet surveys indicate only about 12% of American adults currently take a GLP-1 while 6% have stopped. Gastrointestinal side effects, cost, and insurance gaps drive many discontinuations. Out-of-pocket prices have eased but still reach hundreds of dollars monthly for some. (HealthVerity, June 16, 2025; CDC)
Market Expansion and Pipeline Momentum
Projections point to continued growth. Analysts forecast 25 million to 30 million Americans on GLP-1 therapy by 2030. The global anti-obesity drug market could expand from $19.6 billion in 2025 to $104.9 billion by 2035. Oral formulations approved in late 2025 and higher-dose options under FDA review promise broader access for patients wary of injections. Next-generation candidates such as CagriSema have shown superior weight loss and glycemic control versus semaglutide in recent trials. (JPMorgan, Feb. 27, 2026; DDW Online, Feb. 3, 2026)
Additional signals have emerged. A retrospective cohort of more than 92,000 patients presented at Digestive Disease Week 2026 found GLP-1 and dual-agonist users experienced a 25% lower overall cancer risk, driven largely by reduced skin cancer incidence, though gastrointestinal and liver cancer rates showed no significant change. Long-term safety questions persist. Muscle loss, nutritional deficiencies, and unknown effects beyond four years warrant scrutiny. Bariatric surgery volumes have fallen sharply since 2022, raising concerns that some patients with severe obesity may forgo procedures offering more durable results. (ScienceDaily, Nov. 16, 2025; recent X discussions citing DDW 2026 abstract by Kilani et al.)
So the data paints an encouraging yet incomplete picture. Obesity rates are bending. Cardiovascular events are declining in treated populations. Weight loss reaches levels once considered unrealistic for pharmacotherapy. Yet durability depends on adherence, affordability, and ongoing innovation. Physicians, payers, and policymakers now face a practical question. How to convert early population-level gains into lasting reductions in chronic disease burden without over-relying on medications that demand continuous use.
Further trials will clarify who maintains benefits longest and whether combination approaches with lifestyle intervention or newer multi-agonists can extend effects after treatment ends. For now the trend is unmistakable. After decades of steady increase, the needle on American obesity has finally moved in the right direction.
WebProNews is an iEntry Publication